Details

Autor(en) / Beteiligte

• McDermott, David F
• Huseni, Mahrukh A
• Atkins, Michael B
• Motzer, Robert J
• Rini, Brian I
• Escudier, Bernard
• Fong, Lawrence
• Joseph, Richard W
• Pal, Sumanta K
• Reeves, James A
• Sznol, Mario
• Hainsworth, John
• Rathmell, W Kimryn
• Stadler, Walter M
• Hutson, Thomas
• Gore, Martin E
• Ravaud, Alain
• Bracarda, Sergio
• Suárez, Cristina
• Danielli, Riccardo
• Gruenwald, Viktor
• Choueiri, Toni K
• Nickles, Dorothee
• Jhunjhunwala, Suchit
• Piault-Louis, Elisabeth
• Thobhani, Alpa
• Qiu, Jiaheng
• Chen, Daniel S
• Hegde, Priti S
• Schiff, Christina
• Fine, Gregg D
• Powles, Thomas

Titel

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Ist Teil von

• Nature medicine, 2018-06, Vol.24 (6), p.749-757

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2018

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.